Vanguard® Rapid Resp Intranasal
This family of single-nostril (0.5 mL) respiratory vaccines helps protect dogs from key pathogens associated with Canine Infectious Respiratory Disease (CIRD) and can make administration fast and comfortable.
Indications:
For the vaccination of healthy dogs 8 weeks of age or older against canine adenovirus Type 2 (CAV-2) virus, canine parainfluenza (CPI) virus and Bordetella bronchiseptica (Bb).
3 antigenic combinations:
-
Bb + CPiV + CAV-2
-
Bb + CPiV
-
Bb only
Canine Infectious Respiratory Disease (CIRD)
Infectious respiratory disease in dogs can be caused by many different pathogens, both bacterial and viral. In most instances, the clinical signs will be identical regardless of the infecting pathogen.
Because co-infections frequently occur and may lead to more severe symptoms, a multivalent immunization protocol can help PREVENT THE PREVENTABLE.
Efficacy and Safety Studies
VANGUARD® Rapid Resp has been laboratory and field tested to demonstrate efficacy and safety.
Efficacy Study7
Safety Study8
Duration of immunity (DOI) Studies
VANGUARD® Rapid Resp Intranasal vaccines have the first approved 1-year duration of immunity claim for the Bordetella bronchiseptica, CAV-2 and CPiV fractions.
Bordetella bronchiseptica DOI Study9
CAV-2 DOI Study10
CPiV DOI Study11
Prime Boost
The use of intranasal and parenteral vaccines may help provide the best Bordetella bronchiseptica protection.12
-
When the immune system is exposed to antigens via different routes, a more robust immune response may be achieved
-
Mucosal administration followed by systemic vaccination can help to avoid immune exclusion, specifically in seropositive patients13
BRONCHICINE® CAe – The Booster Shot™
-
Monovalent
-
Parenteral
-
Non-infectious14
-
Non-adjuvanted
United States 
